Figure Legends:
Figure 1. The course of CRP, ferritin, and lymphocyte values on 1st,
3rd, and 5 the days in COVID-19.
REFERENCES:
- COVID-19 Map. [cited March 28,2021]. Available from:
https://coronavirus.jhu.edu/ map.html
- L.H. Calabrese, Cytokine storm and the prospects for immunotherapy
with COVID19, Cleve. Clin. J. Med. 87 (7) (2020 May 11) 389–393,
https://doi.org/10.3949/ ccjm.87a.ccc008, pii: ccc008, Published 2020
Jun 30.
- Lam, C.W., Chan, M.H., Wong, C.K., 2004. Severe acute respiratory
syndrome: clinical and laboratory manifestations. Clin. Biochem. Rev.
25, 121–132.
- The RECOVERY Collaborative Group. Dexamethasone in hospitalized
patients with covid-19-preliminary report. New Engl. J.
Med.2021;384:693-704. DOI:10.1056/ NEJMoa2021436
- Sauñe, Patricia & Bryce-Alberti, Mayte & Portmann-Baracco, Arianna
& Accinelli, Roberto. (2020). Methylprednisolone pulse therapy: An
alternative management of severe COVID-19. Respiratory medicine case
reports. 31.101221.10.1016/j.rmcr.2020. 101221.
- Bhimraj A., Morgan L., R.L Shumaker, A.H., Lavergne, V., Baden, L.,
Cheng, V et al. Infectious Diseases Society of America Guidelines on
the Treatment and Management of Patients with COVID-19. Published by
IDSA on 3/02/2021. Last updated February 3, 2021,
www.idsociety.org/COVID19guidelines.
- World Health Organization (WHO), 2020. Coronavirus Disease (COVID-19)
Situation Dashboard. (Accessed June 28, 2020).
https://www.who.int/emergencies/diseases/ novel-coronavirus-2019.
- Ministry of Health, General Directorate of Public Health. COVID-19
(SARS-CoV-2 Infection) Adult Patient Treatment Scientific Advisory
Board Study, October 9, 2020.
- Tobaiqy M, Qashqary M, Al-Dahery S, et al. Therapeutic management of
patients with COVID-19: a systematic review. Infection Prevention in
Practice. 2020;2(3):100061. doi:10.1016/j.infpip.2020.100061
- Pagliano P, Scarpati G, Sellitto C, Conti V, Spera AM, Ascione T,
Piazza O, Filippelli A. Experimental Pharmacotherapy for COVID-19: The
Latest Advances. J Exp Pharmacol. 2021 Jan 7;13:1-13. doi:
10.2147/JEP.S255209. PMID: 33442304; PMCID: PMC7800714.
- Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H et al. Cytokine storm
intervention in the early stages of COVID-19 pneumonia. Cytokine &
Growth Factor Reviews. 2020;53:38–42. DOI:
10.1016/j.cytogfr.2020.04.002
- Mattos-Silva, P., Felix, N. S., Silva, P. L., Robba, C., Battaglini,
D., Pelosi, P., et al. Pros and cons of corticosteroid therapy for
COVID-19 patients. Respir Physiol Neurobiol. 2020;280:103492.
doi:10.1016/j.resp.2020.103492
- Kolilekas L, Loverdos K, Giannakaki S, et al. Can steroids reverse the
severe COVID-19 induced ‘cytokine storm’? J Med Virol. 2020;92
(11):2866–2869.
- So C, Ro S, Murakami M, Imai R, Jinta T. High-dose, short-term
corticosteroids for ARDS caused by COVID-19: a case series. Respirol
Case Rep. 2020;8(6):e00596. Published 2020 Jun 4. doi:10.1002/rcr2.596
- Chen Q, Song Y, Wang L, et al. Corticosteroids treatment in severe
patients with COVID-19: a propensity score matching study [published
online ahead of print, 2021 Feb 1]. Expert Rev Respir Med.
2021;1-10. doi:10.1080/17476348.2021.1856659
- Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas
SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung
inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2):
anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020
March-April,;34(2):327-331. doi: 10.23812/CONTI-E. PMID: 32171193.
- Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for
2019-nCoV pneumonia. Lancet. 2020;395(10225):683-684.
doi:10.1016/S0140-6736(20)30361-5
- Dai J, Xiong Y, Li H, et al. Corticosteroid treatment in severe
COVID-19 pneumonia: two cases and literature review. Clin Rheumatol.
2020;39(7):2031–2037
- Veronese N, Demurtas J, Yang L, et al. Use of corticosteroids in
coronavirus disease 2019 pneumonia: a systematic review of the
literature. Front Med (Lausanne). 2020;7:170.
- Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B et al. High– Dose Pulse
Versus Nonpulse Corticosteroid Regimens in Severe Acute Respiratory
Syndrome. American Journal of Respiratory and Critical Care Medicine.
2003;168(12):1449–56. DOI: 10.1164/rccm.200306-766OC
- Russell CD, Millar JE, Baillie JK. Clinical evidence does not support
corticosteroid treatment for 2019-nCoV lung injury. Lancet.
2020;395(10223):473–475.
- Bartoletti M, Marconi L, Scudeller L, Pancaldi L, Tedeschi S,
Giannella M, et al,PREDICO Study Group. Efficacy of corticosteroid
treatment for hospitalized patients with severe COVID-19: a
multicentre study. Clin Microbiol Infect. 2021 Jan;27(1):105-111. doi:
10.1016/j.cmi.2020.09.014. Epub 2020 Sep 22. PMID: 32971254; PMCID:
PMC7506332.
- Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute
Respiratory Distress Syndrome and Death in Patients With Coronavirus
Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med.
2020;180(7):934–943. doi:10.1001/jamainternmed.2020.0994
- Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, Rajagopal
S, et al. Cytokine Storm in COVID-19-Immunopathological Mechanisms,
Clinical Considerations, and Therapeutic Approaches: The REPROGRAM
Consortium Position Paper. Front Immunol. 2020 Jul 10;11:1648. doi:
10.3389/fimmu.2020.01648. PMID: 32754159; PMCID: PMC7365905.